Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04968522
Registration number
NCT04968522
Ethics application status
Date submitted
2/06/2021
Date registered
20/07/2021
Titles & IDs
Public title
FASST - Fetal Alcohol Spectrum Stimulant Trial
Query!
Scientific title
Attention Management Trial for Children With FASD - a N-of-1 Control Trial of Prescribed Stimulants for ADHD in FASD
Query!
Secondary ID [1]
0
0
RES-21-0000-248A
Query!
Secondary ID [2]
0
0
RES-21-0000-248A
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
FASST
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Fetal Alcohol Spectrum Disorders
0
0
Query!
Condition category
Condition code
Reproductive Health and Childbirth
0
0
0
0
Query!
Fetal medicine and complications of pregnancy
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Methylphenidate Hydrochloride
Treatment: Drugs - Placebo
Treatment: Drugs - Methylphenidate hydrochloride
Treatment: Drugs - Methylphenidate Hydrochloride 18 MG
Treatment: Drugs - Dexamphetamine sulfate
Placebo comparator: Placebo comparator 2 - Participants will be allocated a randomly allocated sequence of treatment. The randomisation will be in two-week pairs - so the order of treatment (A) and placebo (P) to be randomly assigned within each two-week cycle (over 8 weeks). Placebo will be matched in dose to their stimulant dose at enrolment to the trial as determined and titrated by their primary paediatrician. This dose will remain constant for the course of the trial (8 weeks). Placebo will be orally administered, unless this is not possible for clinical reasons.
Experimental: Stimulant - The stimulants used in the trial are commercially available and will be used in accordance with the approved labelling. Participants must be on a stable dose of stimulant medication for at last 1 month prior to the study. The dose is individualized and titrated by treating primary paediatrician. This will represent the starting dose for the trial, and this will remain stable through the course of the 8-week trial. This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. Based on pilot data from this group, psychostimulant medications prescribed in this population may include:
* Methylphenidate IR
* Methylphenidate LA
* Dexamphetamine
Children will take the required number of capsules to match the total prescribed dose (e.g. 30mg Ritalin LA is 3x10mg capsules).
Treatment: Drugs: Methylphenidate Hydrochloride
This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Ritalin 10 will be administered at the child's prescribed dose and may include a half tablet (5mg) increment. Ritalin 10 will be encapsulated in full tablet (10mg) or half tablet (5mg) dose.
Treatment: Drugs: Placebo
The placebo is Maize Starch and Pregelatinised Maize Starch. The placebo will be encapsulated using the same capsule that is opaque so that participants cannot distinguish the two visually. Where the active mediation amount is small for the capsule, there will be additional Starcke 1500 (Maize Starch and Pregelatinised Maize Starch) added to fill the capsule so that the active drug and capsule also weigh approximately the same. The dose of placebo will be matched to the participants currently prescribed stimulant medication.
Treatment: Drugs: Methylphenidate hydrochloride
This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Ritalin LA will be administered at the child's prescribed total dose. Ritalin LA will be encapsulated.
Treatment: Drugs: Methylphenidate Hydrochloride 18 MG
This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Concerta (18mg) will be administered at the child's prescribed total dose. Concerta will be encapsulated.
Treatment: Drugs: Dexamphetamine sulfate
This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Dexamphetamine (10mg) will be administered at the child's prescribed total dose. Dexamphetamine will be encapsulated.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change in ADHD symptoms - teacher report - between placebo and stimulant
Query!
Assessment method [1]
0
0
ADHD symptoms will be measured using the Conners 3rd Edition-Teacher (Conners 3-T), for 6-18 year old's and the Conners Early Childhood teachers/childcare providers (full length) form for participants 2-6 years. Each item is rated on a Likert scale from 0 to 3 (0=never or rarely; 1=sometimes; 2=often; 3=very often). Test- retest values for the Conners scales indicate excellent temporal stability (ranging from .73 to 1.00).
The T-score is norm referenced, with a mean of 50. The average range falls within one standard deviation of the mean (i.e., between 40 and 59). A higher score indicates more elevated symptoms. T score Guideline 70+Very Elevated Score 65-69 Elevated Score 40-59 Average score 60-64 High average score \< 40 Low score. Investigators will examine Inattentive and Hyperactivity/Impulsivity Symptom Scales. Symptoms indicated for each subscale are summed to get total.
Query!
Timepoint [1]
0
0
Daily for 5 week days (Monday - Friday) of each trial week (8 weeks total)
Query!
Primary outcome [2]
0
0
Change in ADHD symptoms - parent report - between placebo and stimulant
Query!
Assessment method [2]
0
0
ADHD symptoms will be measured using the Conners 3rd Edition-Parent (Conners 3-P), for 6-18 year old's and the Conners Early Childhood parent (full length) form for participants 2-6 years. Each item is rated on a Likert scale from 0 to 3 (0=never or rarely; 1=sometimes; 2=often; 3=very often). Test- retest values for the Conners scales indicate excellent temporal stability (ranging from .73 to 1.00).
The T-score is norm referenced. The average range falls within one standard deviation of the mean (i.e., between 40 and 59). A higher score indicates more elevated symptoms. T score Guideline 70+Very Elevated Score 65-69 Elevated Score 40-59 Average score 60-64 High average score \< 40 Low score. Investigators will examine Inattentive and Hyperactivity/Impulsivity Symptom Scales. Symptoms indicated for each subscale are summed to get the total.
Query!
Timepoint [2]
0
0
Daily for 5 week days (Monday - Friday) of each trial week (8 weeks total)
Query!
Primary outcome [3]
0
0
Change in spatial working memory - between placebo and stimulant
Query!
Assessment method [3]
0
0
Spatial Working Memory (SWM) task from the Cambridge Neuropsychological Test Automated Battery. SWM is a component of cognitive executive function which is measured by SWM task of CANTAB between the errors. The ability to retain spatial information and manipulate remembered items in working memory will be measured with the SWM task of CANTAB which is self-ordered and assesses the individual's ability to strategise. Between search errors will be analysed. Scores are raw scores, with no normative data available. Higher error score indicated poorer performance. Scale does not have a maximum range.
Query!
Timepoint [3]
0
0
Day 3 of each trial week (8 weeks total)
Query!
Primary outcome [4]
0
0
Change in Visual Information Processing - between placebo and stimulant
Query!
Assessment method [4]
0
0
Rapid Visual Information Processing (SOC) from Cantab. SOC Stockings of Cambridge (SOC) is a test of spatial planning that requires individuals to use problem-solving strategies to match two sets of stimuli. The participant must move the balls in the bottom display to copy the pattern shown in the top display. The balls are moved one at a time by selecting the required ball, then selecting the position to which it should be moved. The participant is instructed to make as few moves as possible to match the two pattern.
The outcome measure of this subtest is the number of problems completed, regardless of whether the maximum moves limit was reached on any problem.
Query!
Timepoint [4]
0
0
Day 3 of each trial week (8 weeks total)
Query!
Secondary outcome [1]
0
0
Change in child problem behaviour rating- between placebo and stimulant
Query!
Assessment method [1]
0
0
Top Problem Rating. This will be used as a brief but robust measure of child emotional and behavioural difficulties as rated by the parent. Top Problems Assessment (TPA) is a brief, idiographic procedure that allows clinicians and researchers to identify problems of children that are especially important from the perspective of the caregiver. The severity of these problems, once identified, will monitored daily.
The overall severity of problem rating (0 - 4) between placebo and active medication arms will be used as an indicator of problem worsening or improving. as one index of whether improvement is occurring. A higher problem rating indicates greater perceived difficulties.
Query!
Timepoint [1]
0
0
Daily for 5 week days (Monday - Friday) of each trial week (8 weeks total)
Query!
Secondary outcome [2]
0
0
Change in functional Impairment- between placebo and stimulant
Query!
Assessment method [2]
0
0
Impairment resulting from ADHD symptoms. This scale contains the items that are most likely to represent the participant's target of treatment. The instrument uses a Likert scale such that any item rating 2 or 3 is clinically impaired. The scale is scored generating the total score. When defining impairment for DSM-IV, any domain with at least two items scored 2, one item scored 3 or a mean score \>1.5 is impaired.
Query!
Timepoint [2]
0
0
Daily for 5 week days (Monday - Friday) of each trial week (8 weeks total)
Query!
Secondary outcome [3]
0
0
Difference in side effects during placebo and stimulant phase
Query!
Assessment method [3]
0
0
Investigators will monitor side effects of the placebo and active medication using the Barkley Side Effects Rating Scale (17 symptoms; 0 = absent, severity rated from 1 to 9). Parent ratings of side effects for the drug and placebo conditions will be described using the mean total side effect rating for each condition.
Query!
Timepoint [3]
0
0
Day 5 of each trial week (8 weeks total)
Query!
Secondary outcome [4]
0
0
Trial feasibility - recruitment rate
Query!
Assessment method [4]
0
0
Feasibility of the study (n-of-1 design) will be explored using trial recruitment rate across the trial from study start to study close. Investigators will calculate recruitment feasibility as the percentage of eligible participants agreeing to participate. A higher percentage will indicate greater participation.
Query!
Timepoint [4]
0
0
End of 8 month active trial phase
Query!
Secondary outcome [5]
0
0
Trial feasibility - completion rate
Query!
Assessment method [5]
0
0
Feasibility of the study (n-of-1 design) will be explored using completion rates across the trial from study start to study close. Completion rate will be the percentage of enrolled participants who complete the trial. A higher percentage will indicate greater participation.
Query!
Timepoint [5]
0
0
End of 8 month active trial phase
Query!
Secondary outcome [6]
0
0
Compliance
Query!
Assessment method [6]
0
0
Investigators will inspect participant medication diaries, to calculate treatment compliance. Non-compliance will be defined as missing more than one or more days of the active drug or placebo condition.
Query!
Timepoint [6]
0
0
End of 8 month active trial phase
Query!
Secondary outcome [7]
0
0
Assessment completion rate
Query!
Assessment method [7]
0
0
Investigators will calculate the percentage of outcome assessments completed by each participant to examine assessment feasibility of the study design.
Query!
Timepoint [7]
0
0
End of 8 month active trial phase
Query!
Secondary outcome [8]
0
0
Data completion reason
Query!
Assessment method [8]
0
0
Investigators will also examine reasons for incomplete outcome data.
Query!
Timepoint [8]
0
0
End of 8 month active trial phase
Query!
Secondary outcome [9]
0
0
Adverse events
Query!
Assessment method [9]
0
0
Adverse events (AE's) will be coded using the, Medical Dictionary for Regulatory Activities (MedDRA), and calculated once each per participant. We will describe the total number of AE's across the trial.
Query!
Timepoint [9]
0
0
End of 8 month active trial phase
Query!
Eligibility
Key inclusion criteria
Each patient must meet all of the following criteria to be enrolled in this trial:
* Is between the ages of 4 - 18 years at the time of randomization.
* Meet diagnostic criteria for FASD or at risk of FASD according to the Australian Guide to the diagnosis of FASD.
* Is a patient of VicFAS or Developmental Paediatrics (Monash Health).
* Has a diagnosis of ADHD according to the DMS-IV criteria.
* Be on a stimulant medication for treatment of ADHD symptoms.
* Be on a stimulant medication as a primary treatment for ADHD.
* Be on a stable dose of stimulant medication for at last 1 month prior to the study.
* Provide a signed and dated informed consent form / and has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf.
* If seen by VicFAS/Developmental paediatrics between August 2019 - study commencement date), parent/guardian must have provided verbal or written consent to the VicFAS database PICF and selected 'yes' to the optional consent for contact for 'future research'.
Query!
Minimum age
4
Years
Query!
Query!
Maximum age
18
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria will include any of the following:
* Inability to read or speak sufficient English for either child or parent/guardian to complete assessment tasks.
* Be on a medication for treatment of ADHD symptoms that is a medication other than stimulants as a primary treatment for ADHD.
* Allergy/sensitivity to Starcke 1500 (Maize Starch and Pregelatinised Maize Starch).
* Unable to swallow capsules.
* Intracranial symptoms or pathology such as epilepsy, hydrocephalus, diagnosed traumatic. brain injury or progressive intracranial tumours that may impact cognitive and behavioural function (children with asymptomatic or static lesions will be eligible).
* An abnormal ECG result at the time of screening deemed clinically significant by study physician.
* Presence of a significant comorbid psychiatric or psychological (excluding ADHD, oppositional defiant disorder, conduct disorder and pervasive development disorder/autism spectrum disorder) including depressive disorder, anxiety disorder, psychotic disorder, suicidality, Tic disorder, anorexia or bulimia nervosa
* Has a known hypersensitivity to starch or other compound relevant to placebo/capsules.
* Has had treatment with any other investigational drug within 4 weeks prior to randomisation.
* If the participant is known to be pregnant, they cannot take part in this research project.
* Parent/guardian not consenting to contact with paediatrician or school.
* Is deemed by their treating paediatrician to be medically unsafe for trial participation.
* Child's school unwilling to participate in outcome assessments.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
14/02/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/07/2023
Query!
Actual
Query!
Sample size
Target
20
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Monash Health - Clayton
Query!
Recruitment postcode(s) [1]
0
0
3168 - Clayton
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Monash Medical Centre
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
Monash University
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is a double-blind, placebo controlled, series of N-of-1 trials of individualised stimulant dose on ADHD symptomatology in children with FASD. The broad aim of this study is to contribute new evidence towards understanding treatment efficacy for ADHD symptoms in FASD. Specific aims are: 1. To assess the ongoing effectiveness of stimulant medication prescribed for ADHD symptoms in individual children with FASD of clinically prescribed stimulant medication compared to placebo to control ADHD symptoms (using behavioural and cognitive measures) in children with FASD and ADHD using a N-of-1 trial design. 2. To obtain pilot data to examine feasibility and tolerability of the planned N-of-1 trial design in children with FASD and ADHD for future and larger studies that might seek to examine if the different stimulant types are equally effective relative to placebo. 3. To review the multiple N-of-1 data to analyze key individual factors that mediate the effect of stimulants relative to placebo on ADHD symptoms, including underlying child factors (attention skills, cognitive function), sociodemographic factors and other prenatal exposures.
Query!
Trial website
https://clinicaltrials.gov/study/NCT04968522
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Alison Crichton, PhD
Query!
Address
0
0
Monash Children's Hospital
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Alison Crichton, PhD
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
0428214717
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Undecided
Query!
No/undecided IPD sharing reason/comment
Beginning 3 months following analysis and article publication, the following will be made available long-term for use by future researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept Monash Health institutional conditions for access:
* Group level data that underlie the results reported in this article after de-identification (text, tables, figures and appendices)
* Trial protocol, PICF
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT04968522